ABEONA THERAPEUTICS INC. Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities
ABEONA THERAPEUTICS INC. (ABEO) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities of 614.25 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities · last filed 2026-08-13
- ABEONA THERAPEUTICS INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2025-06-30 was 614.25K shares, a 6.18% increase year-over-year.
- ABEONA THERAPEUTICS INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2024-06-30 was 578.50K shares.
- ABEONA THERAPEUTICS INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2025 was 614.25K shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 6 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 9 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | 614.25K shares 10-K · filed 2026-03-17 | ||||
| 2025-09-30 | 614.25K shares 10-Q · filed 2025-11-12 | ||||
| 2025-06-30 | 614.25K shares 10-Q · filed 2026-08-13 | 614.25K shares 10-Q · filed 2026-08-13 | |||
| 2024-06-30 | 578.50K shares 10-Q · filed 2025-08-14 | 578.50M shares 10-Q · filed 2024-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |